Diagnostic accuracy of spirometry in primary care. by Schneider, A. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/80404
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
BMC Pulmonary Medicine OBioMed Central
Research article
Diagnostic accuracy of spirometry in primary care
Antonius Schneider*1, Lena G indner2, Lisa T ilem ann2, Tjard Schermer3, 
Geert-Jan D inant4, Franz Joachim Meyer5 and Joachim Szecsenyi2
Address: 'Institute o f General Practice, Technische Universität München, München, Germany, 2Departm ent o f  General Practice and Health Services 
Research, University Hospital, University o f Heidelberg, Heidelberg, Germany, 3Departm ent o f Primary Care Medicine, Radboud University 
Nijmegen Medical Centre, Nijmegen, The Netherlands, 4Departm ent o f General Practice, School for Public Health and Primary Care, Maastricht 
University, Maastricht, The N etherlands and 5Departm ent o f Cardiology, Pulm onology and Angiology, Medical Centre, University o f Heidelberg, 
Heidelberg, Germany
Email: Antonius Schneider* - antonius.schneider@ lrz.tum .de; Lena Gindner - lena.gindner@ med.uni-heidelberg.de;
Lisa Tilem ann - lisa.tilem ann@ med.uni-heidelberg.de; Tjard Schermer - T.Schermer@ hag.umcn.nl; Geert- 
Jan D inant - GeertJan.Dinant@ HAG.unimaas.nl; Franz Joachim Meyer - joachim.meyer@ med.uni-heidelberg.de;
Joachim Szecsenyi - joachim.szecsenyi@ med.uni-heidelberg.de
* Corresponding author
Open Access
Published: 10 July 2009 Received: 4 March 2009
BMC Pulmonary Medicine 2009, 9:31 d o i: l0 . l l  86/1471-2466-9-31 Accepted: 10 July 2009
This article is available from : http://www.biom edcentral.cOm /l47l-2466/9/3 1 
©  2009 Schneider e t al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons A ttribu tio n  License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original w o rk  is properly cited.
Abstract
Background: To evaluate the sensitivity, specificity and predictive values of spirometry for the 
diagnosis of chronic obstructive pulmonary disease (COPD) and asthma in patients suspected of 
suffering from an obstructive airway disease (OAD) in primary care.
Methods: Cross sectional diagnostic study of 2 l9  adult patients attending l0  general practices for 
the first time with complaints suspicious for OAD. All patients underwent spirometry and 
structured medical histories were documented. All patients received whole-body plethysmography 
(WBP) in a lung function laboratory. The reference standard was the Tiffeneau ratio (FEV|/VC) 
received by the spirometric maneuver during examination with WBP. In the event of inconclusive 
results, bronchial provocation was performed to determine bronchial hyper-responsiveness (BHR). 
Asthma was defined as a PC20 fall after inhaling methacholine concentration < l6 mg/ml.
Results: 90 (4l.l%) patients suffered from asthma, 50 (22.8%) suffered from COPD, 79 (36.l%) 
had no OAD. The sensitivity for diagnosing airway obstruction in COPD was 92% (95%CI 80-97); 
specificity was 84% (95%CI 77-89). The positive predictive value (PPV) was 63% (95%CI 5l-73); 
negative predictive value (NPV) was 97% (95%CI 93-99). The sensitivity for diagnosing airway 
obstruction in asthma was 29% (95%CI 2l-39); specificity was 90% (95%CI 8l-95). PPV was 77% 
(95%CI 60-88); NPV was 53% (95%CI 45-6l).
Conclusion: COPD can be estimated with high diagnostic accuracy using spirometry. It is also 
possible to rule in asthma with spirometry. However, asthma can not be ruled out only using 
spirometry. This diagnostic uncertainty leads to an overestimation of asthma presence. Patients 
with inconclusive spirometric results should be referred for nitric oxide (NO) -  measurement and/ 
or bronchial provocation if possible to guarantee accurate diagnosis.
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Background
Asthma is a common chronic disease with a high preva­
lence of approx. 5% in industrialized nations. It is charac­
terized by a chronic inflammation process which induces 
bronchial hyper-responsiveness and in most cases, revers­
ible airway obstruction [1]. Another common pulmonary 
disease is chronic obstructive pulmonary disease (COPD) 
which shows irreversible airway obstruction, and which is 
mostly caused by inhaling tobacco smoke [2]. The preva­
lence of COPD is estimated to be around 10% and 
expected to be the fourth most important cause of death 
in 2020 [3]. Due to this high morbidity, general practi­
tioners play a key role in detecting the disease as they see 
patients during the earlier stages of disease. Spirometric 
investigation is seen as a gold standard for diagnosing air­
way obstruction. Therefore, office spirometry is increas­
ingly seen as a quality standard in general practice [4,5].
The efficacy of spirometry in diagnosing COPD was dem­
onstrated by a specialist team, which received referrals for 
performing spirometry and bronchodilator reversibility 
testing in patients suspected of having COPD [6]. The 
DIDASCO Study revealed the difficulty of diagnosing 
COPD with screening questionnaires only and concluded 
that spirometry is essential for early diagnosis [7]. These 
investigations focused on COPD only, which is marked by 
irreversible airway obstruction. The diagnostic value of 
spirometry for diagnosing asthma marked by reversible 
airway obstruction remains unclear. This is of importance, 
as asthma needs to be diagnosed by bronchial provoca­
tion testing when spirometry shows no airway obstruction 
[8]. One diagnostic study in primary care used spirometry 
and bronchial provocation testing for identifying patients 
with asthma and COPD [9]. However, this was only car­
ried out in patients complaining of suffering from a 
cough; and spirometry was performed by a single special­
ist. Spirometry and bronchial provocation testing were 
also used in the DIMCA study [10]. Indeed this was a 
screening study performed in a specialist center to detect 
patients in early stadiums of asthma or COPD.
Due to the design of these asthma and COPD trials, there 
is no evidence of the diagnostic accuracy of spirometry 
itself. Therefore, the true degree of the associated diagnos­
tic uncertainty for patients with complaints suspected of 
having an airway obstruction remains unclear. The need 
for closing this gap of knowledge has been pointed out 
several times [11,12]. The difficulty is that the pretest 
probability of a disease and its severity in primary care is 
lower when compared to a hospital setting, thus hamper­
ing the predictive values of diagnostic tests [13,14]. There­
fore, test results evaluated in hospital settings can not 
easily be transferred into general practice [15]. The aim of 
this study was to investigate the sensitivity, specificity and
predictive values of spirometry for diagnosing airway 
obstruction in asthma and COPD in general practice.
Methods 
Design and sample
This cross-sectional study was performed between January 
2006 and December 2007 with fourteen general practi­
tioners (GPs) working in ten general practices. 219 
patients visiting their GP for the first time with complaints 
suggestive of obstructive airway disease (OAD) were con­
secutively included in each practice. Patients visited their 
GPs with symptoms such as dyspnea, coughing or expec­
toration. Their medical history was taken with a structured 
questionnaire. The patients had not been diagnosed pre­
viously for OAD and they had not received any previous 
anti-obstructive medicine. Other exclusion criteria related 
to well known contra-indications for bronchodilator 
reversibility testing or bronchial provocation, namely 
untreated hyperthyreosis, unstable coronary artery dis­
ease, and cardiac arrhythmia. Pregnancy also led to exclu­
sion. The study was approved by the Medical Ethics 
Committee of the University of Heidelberg. Patients gave 
written informed consent.
On the basis of the pilot study [16] we estimated the pre­
test probability of asthma as being 45% and of COPD as 
16%. We estimated the sensitivity for diagnosing asthma 
to be 30% and the specificity to be 90%. The sensitivity 
and specificity for finding COPD was each estimated to be 
90%. Power calculations showed that we had to include at 
least 208 patients to determine the sensitivities and specif­
icities with a 95% confidence interval of ± 10% [17]. The 
diagnostic values of spirometry in general practice were 
calculated separately for each asthma and COPD group to 
avoid confusion. The diagnostic value for diagnosing 
asthma under optimal conditions was investigated by 
pooling all patients and determining the sensitivity, spe­
cificity and predictive values of spirometric maneuvers of 
the lung function laboratory.
Index test: Spirom etry in general practice
Ten general practices were equipped with the same elec­
tronic spirometer (Medikro SpiroStar USB®) and associ­
ated spirometry software. The spirometer was a hand-held 
instrument for lung function testing that has to be con­
nected via USB device to a computer. Spirometric data, 
flow-volume and volume-time graphs are displayed in 
real-time on the personal computer as the patient per­
forms the spirometry test. A calibration file saves the cali­
bration data for internal quality assurance. Instrument 
performance is regularly monitored and performance 
deviations are identified by the software. The software 
also compares the measured values with reference tables. 
The best of three consecutive spirometry recordings was 
used in accordance with the guidelines of the European
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Respiratory Society [18]. The maximal inspiratory and 
expiratory flow volume curves were generated by forced 
deep inspiration and expiration with short intervening 
periods of tidal breathing; patients used a nose clip. The 
maneuver was performed in a sitting position. Patients 
with a FEV1 (forced expiratory volume in one second) < 
80% of predicted received a bronchodilation test with an 
additional performance of spirometry 20 minutes after 
inhaling salbutamol. Obstructive airway disease was diag­
nosed if FEV1/VC < 70% and/or FEV1 < 80% [4,5]. 
Obstruction was considered to be reversible on salbuta- 
mol (which indicates a diagnosis of asthma) if the bron­
chodilation response A FEV1 was >12% of the baseline 
and >200 ml [4] and norm  values were reached. GPs were 
asked to make their diagnoses based on the test results.
All of the GPs were appropriately trained in the key 
aspects of the diagnosis and management of asthma and 
COPD, as well as in performing and interpreting spirom­
etry during two educational meetings. The practice assist­
ants completed an intensive 6-hour course and were 
trained in performing and interpreting spirometry. Two 
outreach visits were also performed with repeated individ­
ual education at a direct, practical level, until the optimal 
performance of the spirometry was secured.
Reference test: Bodyplethysmography and bronchial 
provocation
After diagnosis by their GP, all patients were referred to 
the lung function laboratory of the University Medical 
Hospital at once for investigation with whole-body 
plethysmography (WBP). If therapy was necessary due to 
asthma or COPD, it was initiated by the GP. However, 
patients were instructed not to use any bronchodilator or 
inhaled steroid twelve hours before visiting the lung func­
tion laboratory. Spirometry is normally the routine 
m ethod for measuring the lung volume required to diag­
nose airflow obstruction -  i.e. (forced) vital capacity 
((F)VC) or FEV1. However, spirometry is no t capable of 
providing information about intrathoracic residual vol­
ume or total airway resistance. A WBP is required to meas­
ure residual volume (RV), functional residual capacity 
(FRC), and total lung capacity (TLC). Therefore, the 
advantage of WBP over spirometry is that it is able to dis­
tinguish between restrictive and obstructive processes. 
Additionally, the resistance to airflow can be evaluated 
and the response of airway resistance, airway conductance 
and thoracic gas volume can be determined in response to 
bronchodilator reversibility testing and bronchial provo­
cation. In particular circumstances, measurement of these 
lung volumes are strictly necessary for a correct physiolog­
ical diagnosis [19,20]. However, as WBP is only common 
in highly developed health care systems and the added 
value on top of spirometry remains unclear, it is only rec­
ommended in a few guidelines [21-23].
M easurem ent technique o f  whole-body plethysmography and 
bronchial provocation
During WBP, the patient sits inside an airtight chamber 
and makes respiratory efforts against the closed shutter, 
causing chest volume to expand and decompressing the 
air in the lungs. The increase in chest volume reduces the 
box's volume, thus increasing the pressure in the box. The 
procedures were performed according to standard proto­
cols [21]. Lung function reference values that had been 
adjusted for sex, age, and height were used [24]. Patients 
with FEV1 < 80% of predicted received a bronchodilation 
test with an additional performance of WBP 20 minutes 
after inhaling salbutamol. An obstructive airway disease 
was diagnosed if FEV1 < 80% and/or FEV1/VC < 0.70. The 
obstruction was classified as reversible on a salbutamol 
(indicating asthma) when A FEV1 was >12% and >200 ml 
from the baseline value [4] and norm  values were reached. 
In all other cases, the obstruction was classified as not 
reversible (Figure 1). If there was no bronchial obstruc­
tion, bronchial provocation was performed to determine 
bronchial hyper-responsiveness (BHR). Bronchial provo­
cation is considered to be the best method for diagnosing 
asthma [25], although there is conflicting evidence [26], 
probably arising from variations in the population stud­
ied, as the diagnostic value increases with pre-test proba­
bility of the disease [27]. Trained lung function 
technicians measured bronchial hyper-responsiveness to 
methacholine according to the ATS guideline [8]. A diag­
nosis of 'asthma' was made if there was a 20% fall in FEV1 
(PC20) from the baseline value after inhaling metha- 
choline stepwise until the maximum concentration (16 
mg/ml). The pneumologist was blinded against the diag­
nosis of the GP.
D a ta  analysis
The baseline data were presented descriptively. The sensi­
tivity, specificity, and predictive values of the spirometric 
investigation (FEV1 and/or FEV1/VC) in general practice 
were calculated with two-by-two contingency tables with 
the diagnosis of the pneumologist (WBP and bronchial 
provocation) as 'gold standard'. The data were analyzed 
with SPSS 15.0 for Windows. 95% confidence intervals 
were calculated using Wilson's m ethod [28] with the sta­
tistical package CIA (Confidence Interval Analysis) [29]. 
An explanation of how to interpret PPV and NPV is pro­
vided in figure 2.
Results
Study population
A total of 293 patients were assessed for eligibility (Figure
3). 74 patients received spirometry but did no t want to 
receive whole body plethysmography and eventually 
bronchial provocation. Therefore, altogether 219 patients 
participated in the study (127 [57.7%] were female) 
(Table 1). The average age was 43.8 years. The average
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Figure!
Diagnostic decision making with the reference standard (whole-body plethysmography and bronchial provoca­
tion) in the lung function laboratory (COPD = Chronic obstructive pulmonary disease; OAD = obstructive air­
way disease).
body mass index (BMI) was 25.3 (SD 4.4). Of the partici­
pating patients, 78 (35.6%) showed airway obstruction in 
general practice and 138 (63.0%) no abnormal findings 
in spirometry (Figure 3). Three spirometric results were 
lost to follow-up. According to the diagnostic decision 
making in the lung function laboratory, 90 (41.1%) 
patients had asthma, 50 (22.8%) of the participating 
patients had irreversible airway obstruction (COPD), and 
79 (36.1%) showed no abnormal findings. A diagnosis of 
asthma was made in 76 of the cases with bronchial prov­
ocation, with only 14 patients identified solely on the 
basis of bronchodilator reversibility testing. The decision 
that the bronchial provocation was positive was made in 
74 cases by 20% fall of FEV1 and in two cases by extreme 
increase of airway resistance accompanied by develop­
m ent of clinical symptoms of asthma during bronchial 
provocation. There were no significant differences in sex 
(p = 0.719) or obesity (BMI > 30) (p = 0.272) between the 
diagnoses (chi-square test).
Performance of spirometry in general practice
Spirometry was performed with full adherence to ERS 
guidelines in 86 (39.8%) cases (Table 2). There was m od­
erate adherence to ERS in 82 (38.0%) cases. In 48 (22.2%) 
cases the ERS criteria were not fulfilled. E.g., the flow-vol- 
ume curves were deformed or not exactly reproduced. 
Altogether, 78 (36.1%) spirometric maneuvers showed 
airway obstruction. However, a bronchial reversibility test 
was only performed in 37 (47.4%) of these 78 cases.
Estimates of diagnostic accuracy o f spirometry in general 
practice
In relation to the COPD diagnosis, 26 patients were diag­
nosed false positive (Table 3). 12 of these spirometric 
maneuvers showed full/moderate adherence, and 14 were 
not according to guidelines. Four patients were diagnosed 
as false negative as the forced maneuvers in spirometry 
were performed weakly, thus resulting in a virtually nor­
mal Tiffeneau ratio. In these cases was FEV1 > 80% of pre­
dicted and FEV1/VC < 0.70 in the WBP as reference 
standard. Sensitivity was 92% and specificity 84%. Thus 
the pretest probability could be enhanced reasonably 
from 23% to a posttest probability (PPV) of 63%; and 
COPD could be ruled out with high certainty (NPV 97%).
63 patients with asthma were diagnosed false negative as 
they showed no abnormal findings in spirometry (Table
4). It was only possible to identify them through bron­
chial provocation. Eight patients were diagnosed false 
positive; two of these spirometric maneuvers showed 
good adherence, and six were not according to guidelines. 
The pretest probability was enhanced from 41% up to 
77%. However, asthma could not be ruled out, since NPV 
(53%) was similar to the pretest probability of 'not having 
asthma' (1-p = 59%); and 1-p was within the confidence 
interval of NPV (95%CI 45-61). The spirometric results as 
a part of the WBP investigation in the lung function labo­
ratory are given in Table 5. Only 14 patients were identi­
fied by airway obstruction FEV1 < 80% of predicted and
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D is e a s e N o  D is e a s e
Test p o s i t iv e Right pos itive  
a = 72
False positive  
b = 9
81
n e g a t iv e False nega tive  
c = 4 8
Right nega tive  
d = 171
219
Tota l 120 180 300
Pretest probability of having the disease (p): is the prevalence of disease in the investigated population
Pretest probability of not having the disease (1-p): is the prevalence of healthy subjects in the investigated population
Sensitivity (sens): is the proportion of people with disease who have a positive test
Specificity (spec): is the proportion of people free of a disease who have a negative test
Positive predictive value (PpV): probability that a patient with a positive test has got really the disease
Negative predictive value (NPV): probability that a patient with a negative test is really healthy
p = a+c/a+b+c+d = 40%
1-p = b+d/a+b+c+d = 60%
sens = a/a+c = 60%
spec = d/b+d = 95% :
PPV = a/a+b = 89%
NPV = d/c+d = 78%
P re te s t p ro b a b ili ty  (p)
This example illustrates, that a test is useful when the pretest probability is increased up to a reasonable PPV (rule in the disease) or 
when NPV is increased reasonably (rule out). The figures illustrate that specificity is more important to rule in (spin = specificity rule in); 
and that sensitivity is more important to rule out (snout = sensitivity rule out). The relation between p, sens, spez, PPV and NPV is 
described by the Bayes' Theorem. Indeed a test is only useful, if the pretest probability (p) is out of the range of 95%CI of PPV (in this 
example 95%CI = 80%-94%); and/or if the pretest probability of not having the disease (1-p) is out of the range of the 95%CI of NPV 
(in this example 95% CI = 72%-83%). The 95%CI is calculated using W ilson 's m ethod.28
In this example p is increased up to a meaningful PPV. NPV seems not to be increased reasonably if compared with 1-p.
Figure2
Calculation example for the relation between pretest probability, sensitivitiy, specificity, positive predictive 
value (PPV) and negative predictive value (NPV).
positive bronchial reversibility testing. In addition to this, 
under these optimal conditions with optimal differentia­
tion between asthma and COPD, the sensitivity for diag­
nosing asthma solely on basis of spirometric maneuvers 
was only 16%. Again, NPV was similar to the pretest prob­
ability of 'not having asthma'.
Diagnostic decision making by the GPs
The comparison of the diagnoses by the general practi­
tioners with the diagnoses of the pneumologists dem on­
strated a reasonable agreement with respect to COPD 
(Table 6). Additionally, the GPs suspected asthma cor­
rectly in 76.7% of asthma cases despite the diagnostic 
uncertainty using spirometry. Indeed the prevalence of 
asthma was overestimated with 58.2% of healthy subjects 
suspected of having asthma; and 7.8% of patients with 
asthma were considered to be healthy.
Discussion
To our knowledge, this is the first study evaluating the 
diagnostic accuracy of spirometry for diagnosing airflow 
obstruction in  patients with asthma or COPD in primary 
care. We found that the use of spirometry is feasible 
within general practice after training GPs and practice 
nurses. Under these conditions, the presence or absence of 
COPD can be estimated with a comparatively high diag­
nostic accuracy. It is also possible to rule in  asthma. How­
ever, it was impossible to rule out asthma as the sensitivity 
was too low.
The prevalence of COPD is increasing in  nearly all coun­
tries of the world and a high diagnostic accuracy is a pre­
requisite of optimal therapeutic management. The 
im portant role of spirometry for diagnosing airway 
obstruction has already been demonstrated [6,7,30,31]. 
However, the diagnostic accuracy of spirometry for diag-
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Figure 3
Flow chart of inclusion and diagnostic work up (COPD = Chronic obstructive pulmonary disease; OAD = 
obstructive airway disease; OAD = obstructive airway disease).
T a b le  1: C h a ra c te r is t ic s  o f  th e  s tu d y  p o p u la tio n . V a lues a re  n u m b e r (p ro p o r t io n )  o r  m ean  
C O P D  = C h ro n ic  o b s tru c tiv e  a irw a y  disease (n  = 219)
(S D ); O A D  = o b s tru c tiv e  a irw a y  disease;
O v e ra ll 
n (%)
A s th m a
n (%)
C O P D
n (%)
N o  O A D
n (%)
n 219 (100) 90 (100) 50 (100) 79 (100)
Female 127 (57.7) 55 (61.1) 26 (54.1) 46 (58.2)
Obesity 30 (13.7) 8 (8.9) 10 (20.0) 12 (15.2)
Age (mean in years [sd]) 43.8 [15.6] 37.9 [14.4] 56.9 [11.5] 42.1 [14.4]
D o you sometimes suffer fro m  shortness o f breath? (yes) 135 (61.4) 55 (61.1) 39 (76.3) 41 (51.9)
Have you suffered fro m  wheezing in you r chest? (yes) 108 (49. 1) 47 (52.2) 30 (63.2) 30 (38.0)
D o you often suffer fro m  a cough? (yes) 126 (57.3) 39 (43.3) 32 (65.8) 55 (69.6)
D o you often suffer fro m  expectoration? (yes) 74 (33.6) 22 (24.4) 20 (36.8) 32 (40.5)
Have you been w oken up w ith  a feeling o f tightness in you r chest? (yes) 49 (22.3) 27 (30.0) 9 (10.5) 13 (16.5)
Have you been w oken up by an attack o f shortness o f breath? (yes) 48 (21.8) 24 (26.7) 10 (18.4) 14 (17.7)
Have you suffered an asthma attack? (yes) 14 (6.4) 1 1 (12.2) 2 (2.6) 1 (1.3)
D o you suffer fro m  any nasal allergies? (yes) 92 (41.8) 44 (48.9) 14 (31.6) 34 (43.0)
D o you often suffer fro m  a com m on cold? (yes) 73 (33.2) 18 (20.0) 18 (26.3) 37 (46.8)
D o you smoke o r  did you smoke? (yes) 1 18 (53.4) 35 (38.9) 43 (86.8) 39 (49.4)
H ow  much do/did you smoke? (mean in pack year [SD]) 11.6 [17.7] 6.6 [12.9] 28.8 [21.7] 6.4 [11.9]
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In te r p r e ta t io n  o f  f lo w -v o lu m e  c u rv e n (%) B ro n c h o d ila t io n  te s t n (%)
Full adherence to  ERS 86 (39.8)
Adherence to  ERS bu t only tw o  flow -vo lum e curves 69 (3 1.9)
N o  adherence to  ERS but firs t flow -vo lum e curve perfect and showing no pathological 13 (6.0) 
signs
N o  adherence to  ERS showing no obstruction 15 (6.9)
N o  adherence to  ERS indicating airway obstruction 33 (15.2)
W as n o t necessary 138 (36.1)
W as necessary and perform ed 37 (17.1) 
W as necessary but n o t perform ed 41 (19.0)
T a b le  3: 2 *  2 ta b le  o f  s p iro m e try  fo r  d ia g nos ing  a irw a y  
o b s tru c tio n  in p a tie n ts  w ith  C O P D  (n  = 208; a s th m a  p a tie n ts  
w ith  FE V | <80% o f  p re d ic te d  in g e n e ra l p ra c tic e  and  in  lung  
fu n c tio n  la b o ra to ry  e xc lu d e d )
CO PD  N o  COPD
Spirom etry + 44 26
Spirom etry - 4 134
208
Pretest probability o f having C O PD  23%
Pretest probability o f n o t having C O PD  77%
Sensitivity 92% (95%CI 80-97)
Specificity 84% (95%CI 77-89)
PPV 63% (95%CI 51-73)
NPV 97% (95%CI 93-99)
nosing COPD has been unknown up to now, thus leading 
to diagnostic uncertainty in suspected cases of COPD. Our 
results demonstrate that the pretest-probability of 22% of 
patients presenting themselves with complaints sugges­
tive of airway obstruction can be increased up to a post­
test probability of 63% for having COPD. This compara­
tively low PPV might be surprising, as the sensitivity was 
84% and specificity was 92%. However, this is explainable 
by the low pretest probability. Another reason might be 
due to sub-maximal maneuvers, leading to false positive 
results by underestimation of FEV1 [11]. As a conse­
quence, more efforts in  terms of continuous education 
would be necessary for an improvement of performance 
and an interpretation of spirometry. Nevertheless, COPD
T a b le  4: 2 x 2 ta b le  o f  s p iro m e try  fo r  d ia g n o s in g  a irw a y  
o b s tru c tio n  in  p a tie n ts  w ith  a s th m a  in g e n e ra l p ra c tic e  (n  = 168; 
p a tie n ts  w ith  C O P D  e xc lu d e d )
asthma no asthma
can be definitively excluded (NPV 97%) when spirometry 
is performed optimally. For these reasons, spirometry 
should be used regularly for diagnosing and managing 
COPD in primary care.
In contrast to these promising results is the limited value 
of spirometry in  excluding asthma. This might be 
explained by the reversibility of airway obstruction in 
asthma. It proved possible to speculate that patients with 
mild or moderate asthma show no airway obstruction 
when spirometry is performed. In these cases, it was nec­
essary for the GP to estimate the presence or absence of 
asthma on the basis of the patient history and inconclu­
sive spirometry. This was misleading in  53 (24.2%) of 
cases (46 patients false positive and 7 patients false nega­
tive). Therefore, alternative methods need to be found for 
diagnosing asthma in  primary care. Guidelines recom­
m end using the measurement of peak-flow-variability to 
diagnose asthma in case of inconclusive spirometry. How­
ever, the low diagnostic value of peak-flow-variability in 
primary care has already been demonstrated [32]. The 
SAPALDIA study, which used an epidemiologic approach, 
has also shown a poor diagnostic value [33]. The measure­
ment of exhaled nitric oxide (NO) which is elevated in 
eosinophilic airway inflammation [34] has been shown to 
be more promising [35], although the technology is 
expensive. Therefore, patients suspected of having asthma 
might be tested with NO measurement or should be 
referred for bronchial provocation if possible to guarantee
T a b le  5: 2 x  2 ta b le  o f  s p iro m e try  fo r  d ia g nos ing  a irw a y  
o b s tru c tio n  in p a tie n ts  w ith  a s th m a  in lu n g  fu n c tio n  la b o ra to ry  
(a ll p a tie n ts  in c lu d e d  w ith  d if fe re n t ia t io n  b e tw e e n  a s th m a  and  
C O P D )
asthma no asthma
Spirom etry + 
Spirom etry -
26
63
8
71
168
Pretest probability o f having asthma 41% 
Pretest probability o f no t having asthma 59% 
Sensitivity 29% (95%CI 21-39)
Specificity 90% (95%CI 81-95)
PPV 77% (95%CI 60-88)
NPV 53% (95%CI 4 5 -6 l)
Spirom etry + 
Spirom etry -
14
76
0
129
219
Pretest probability o f having asthma 41% 
Pretest probability o f n o t having asthma 59% 
Sensitivity 16% (95%CI 10-24)
Specificity 100% (95%CI 97-100)
PPV 100% (95%CI 79-100)
NPV 63% (95%CI 56-69)
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P n e u m lo g is t\G P  A s th m a  C O P D
n (%) n (%)
Asthma (n = 90) 69 (76.7) 14 (15.5)
C O PD  (n = 50) 7 (16.2) 41 (82.0)
N o  O A D  (n = 79) 46 (58.2) 8 (10.1)
accurate diagnosis. Nevertheless, spirometry should be 
used in  diagnosing asthma, as the positive predictive 
value has been comparatively high in  general practice.
One important limitation was that 22% of the spirometric 
maneuvers were not performed correctly in  general prac­
tice. However, with the analysis of the spirometric maneu­
vers as part of the WBP investigation in the lung function 
laboratory, we received accurate diagnostic values of 
spirometry. Our results revealed that the predictive values 
of general practice were slightly lower than in  the lung 
function laboratory. In addition to this, it was not possi­
ble to include all patients consecutively, as some patients 
were not willing to travel to the lung function laboratory 
of the Medical Hospital. This might have led to an overes­
timation of the diagnostic accuracy of spirometry [36]. 
However, that would also emphasize the impossibility of 
excluding asthma solely with spirometry. Another limita­
tion is due to the choice of the cut-off points. Our use of 
the ratio FEV1/VC < 0.70 as is still recommended by 
GOLD [5] may have led to some overestimation of airway 
obstruction in older patients [37] and underestimation in 
younger patients [38]. The ATS/ERS guideline therefore 
suggests using lower limits of normal, which is statistically 
defined by the 5th lower percentile of a reference popula­
tion, to provide more accurate diagnoses [19]. This diag­
nostic algorithm was not integrated in  the spirometric 
software at the time of our study. Moreover, we are aware 
of the limitations of a one-off lung function test to deter­
mine a final diagnosis, as a negative bronchodilator 
response can occur due to fixed airway obstruction in 
asthma. A trial of steroids might have been necessary to 
differentiate between asthma and COPD in some patients. 
Nevertheless, these limitations do not ham per our finding 
that asthma cannot be excluded solely with spirometry. 
The WBP showed little added value on top of spirometry. 
We used it as a reference standard to distinguish between 
overlapping diseases, COPD and restrictive lung disorder. 
However, we only experienced two changes in making the 
diagnosis with the added information of WBP. In two 
patients suffering from dyspnea attacks, the airway resist­
ance was very high during bronchial provocation, but 
FEV1 remained normal. Moreover, we found no patient 
with restrictive lung disorder, which indicates a low prev­
alence in primary care settings. Therefore, the added value 
of WBP for primary care is limited and it should be
N o  O A D  R e s tr ic t iv e  lu n g  d isease
n (%) n (%)
7 (7.8) 0 (0)
1 (2.7) 1 (0)
25 (31.6) 0 (0)
reserved for patients who are difficult to diagnose and 
show persistent complaints.
It was no t possible to specify the alternate diagnosis of the 
patients with no OAD, which is a typical problem of diag­
nostic studies in  primary care. It was impossible to per­
form every investigation (e.g. gastroscopy to determine 
gastro-oesophageal reflux; x-ray) until a definite diagnosis 
could be made. This would not have been allowed by the 
Ethics Committee. However, this limitation does not alter 
the results of spirometric investigation. Finally, the partic­
ipating GPs and practice assistants were highly motivated 
and received intensive training. Nevertheless, 22% of the 
spirometric maneuvers showed no guideline adherence. 
In particular bronchodilation testing was not performed 
regularly which might be due to organisational reasons 
and time constraints in  general practice. The GPs esti­
mated fourteen patients to suffer from COPD. However, 
the final pneumologists' diagnosis of these patients was 
asthma due to positive bronchodilator testing. Therefore, 
this lack of performance led the GPs to over-estimate 
COPD and under-estimate asthma in patients with airway 
obstruction. This is of importance as patients with asthma 
need to be treated preferably with inhaled steroids. How­
ever, our results are better than demonstrated by Mirav- 
itlles et al. [39], which might be due to the repeated 
education of the whole practice team. Nevertheless, these 
results are not satisfying enough. Further efforts are neces­
sary to improve the performance of spirometry, as this 
could enhance the diagnostic accuracy. It has already been 
established that GPs are able to perform and interpret 
spirometry after educational meetings [40] and that per­
forming spirometry has a positive impact on medical deci­
sion making [6,30,41]. It therefore seems reasonable and 
valuable to implement high quality spirometry in primary 
care.
Conclusion
COPD can be estimated with high diagnostic accuracy 
using spirometry. It is also possible to rule in  asthma with 
spirometry. However, asthma can not be ruled out only 
using spirometry. This diagnostic uncertainty leads to an 
overestimation of asthma presence. Patients with incon­
clusive spirometric results should be referred for NO -  
measurement and/or bronchial provocation if possible to 
guarantee accurate diagnosis.
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